Table 1 Clinical features of the study population (n = 108)
Age at diagnosis | 52 (26–79) |
Personal history of cancer | 8.3% (9/108) |
Family history of cancer | 21.3% (23/108) |
FIGO Stage | |
FIGO stage I | 45.3% (48/106) |
FIGO stage II | 17.0% (18/106) |
FIGO stage III | 29.2% (31/106) |
FIGO stage IV | 8.5% (9/106) |
Extent of debulking | |
Residual disease = 0 cm (%) | 79.4% (81/102) |
Residual disease ≤1 cm (%) | 88.2% (90/102) |
Platinum response | |
Platinum-sensitive | 69.6% (71/102) |
Platinum-resistant | 30.4% (31/102) |
Follow-up time (mean, range) | 46 (1–178) |
Disease status at last follow up | |
Dead (%) | 46.1% (48/104) |
Alive with disease (%) | 20.2% (21/104) |
No evidence of disease | 33.7% (35/104) |